Myrbetriq 2014 report

Myrbetriq 2014 report
Myrbetriq 2014 report
Posted in

[sf_modal header=”Sample Report Request” btn_colour=”lightgrey” btn_type=”standard” extraclass=”280-width” btn_size=”small” btn_text=” REQUEST A FREE SAMPLE”]

    Name (required)

    Company (required)

    Email Address (required)

    [/sf_modal]

    [sf_button colour=”lightgrey” link=/reports/ target=”_self”  dropshadow=”no” extraclass=”set_t_width”]FIND ANOTHER REPORT[/sf_button]

    Myrbetriq 2014 U.S. PROMOTIONAL AUDIT REPORT

    Published July 2015 • 25 Pages

    The 5 Key Questions Addressed by this Report:

    • How many physicians were reached by Myrbetriq through personal promotion in 2014 and how does this compare to its peer set in the Overactive Bladder market?
    • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
    • How does Astellas’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Obstetrics/Gynecology, and Urology) and how does this compare to its peers and the overall set of rep-accessible physicians?
    • How often are physicians receiving paid meals for Myrbetriq throughout the year (e.g., monthly, quarterly, annually)?
    • Who were the most detailed prescribers and top paid speakers/consultants for Myrbetriq in 2014?

    Data Sources and Methodology:

    • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
    • Over 125,900 paid interactions across 34,600 physicians made on behalf of Myrbetriq were carefully examined to support our analysis. In addition, interaction data from 3 peer products (e.g. Botox, Toviaz, and VESIcare) was leveraged to provide benchmarking and market insights.